Canadian drug maker Valeant Pharmaceuticals International, Inc. on Tuesday reported a loss for the fourth quarter, citing softer than expected sales in the gastrointestinal business. Adjusted earnings per share missed analysts’ expectations and the company also lowered its financial outlook for the first quarter as well as fiscal 2016.